Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded,prospective study

Han, Changsu; Wang, Sheng Min; Kwak, Kyung Phil; Won, Wang Yeon; Lee, Hwa Young; Chang, Chia Ming; Tang, Tze Chun; Pae, Chi Un

doi:10.1016/j.jpsychires.2015.04.020

Cited by 31 publications

(20 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notwithstanding, a randomized, direct comparison study of 101 individuals with MDD reported that aripiprazole augmentation was superior to antidepressant switching in individuals with current depressive episode despite adequate antidepressant dosage. 34 Similarly, post hoc analyses from the pivotal trials of aripiprazole as augmentation in MDD indicate that nonresponse to the index conventional antidepressant (or worsening on the index antidepressant) was highly associated with response and remission with aripiprazole augmentation. 35,36 The U.S. Food and Drug Administration (FDA)approved treatment strategies as augmentation are quetiapine, olanzapine-fluoxetine combination, aripiprazole, and more recently, brexpiprazole.…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Treating to target in major depressive disorder: response to remission to functional recovery

2015

View full text Add to dashboard Cite

Treating to target in chronic diseases [e.g. Major Depressive Disorder (MDD)] fosters precision, consistency, and appropriateness of treatment selection and sequencing. Therapeutic target definitions/endpoints in MDD should satisfy patient-, provider-, and societal expectations. Functional recovery in depression and return to both physical and mental health are the overarching therapeutic objectives. Treating to target in MDD implies multidimensional symptomatic remission, with a particular emphasis on cognitive function and aspects of positive mental health. Several atypical antipsychotic agents (i.e. brexpiprazole, aripiprazole, quetiapine) are FDA-approved as augmentation agents in MDD. Vortioxetine, duloxetine, and psychostimulants have evidence of independent, direct, and robust effects on cognitive function in MDD. Vortioxetine is the only agent that demonstrates efficacy across multiple cognitive domains in MDD associated with functional recovery. Measurement-based care, health information technology/systems, and integrated care models (e.g. medical homes) provide requisite tools and health environments for optimal health outcomes in MDD. Achieving remission in MDD does not equate to health. Return to positive mental health as well as full functioning provide the impetus to pivot away from traditional provider-defined outcomes toward an inclusive perspective involving patient- and society-defined outcomes (i.e. optimization of human capital). As in other chronic diseases, treating to target (e.g. cognitive function) further increases the probability of achieving optimal health outcomes.

show abstract

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Treating to target in major depressive disorder: response to remission to functional recovery

2015

View full text Add to dashboard Cite

show abstract

“…A 6-week, randomized, rater-blinded, direct comparison study compared aripiprazole augmentation (n=52) and antidepressant switching (n=49) in patients with MDD. 30 The mean change in the MADRS score from the baseline was significantly higher in the aripiprazole augmentation group, with a difference in magnitude of –8.7 (p<0.0001), with the intergroup difference first observed in week 2. The numbers of responders (60% vs. 32.6%, p<0.01) and remitters (54% vs. 19.6%, p<0.0001) were also significantly higher in the aripiprazole augmentation group compared with the switching group.…”

Section: The Current Market Statusmentioning

confidence: 85%

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

et al. 2016

Self Cite

View full text Add to dashboard Cite

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.

show abstract

“…Criteria for evaluating depressive state: The score of self-rating depression scale (SDS) was higher than 0.5. The methods for rating PSQI and SDS were as reported in previous literature [12,13]. Criteria for exclusion (1) Any patients with insomnia arising from systemic diseases such pain, fever, cough, surgery etc., and external environmental interference factors or craniocerebral trauma; (2) pregnant or lactating women; (3) patients with a drug allergy history; (4) any patients below 18 years or above 65 years; (5) any patients complicated by severe primary diseases such as cardiovascular, pulmonary, hepatic, and renal and hemopoietic systems and severe brain organic diseases and mental disorders; (6) alcoholics, and/or psychoactive drug substance and drug abusers and reliers (including hypnotics); (7) any patients who could faint during acupuncture treatment and could not tolerate acupuncture therapy; (8) any patients who did not meet the inclusion criteria and did not take the drug as specified; failure to judge therapeutic effect, incomplete data etc., which could affect the judgment on the therapeutic effect and safety [14].…”

Section: Diagnostic Criteria For Casesmentioning

confidence: 99%

Research on Treating Insomnia Accompanied With Depression by Mongolian Medical Warm Acupuncture

Jin

et al. 2018

Phys Med Rehab Kuror

View full text Add to dashboard Cite

Objective To observe the therapeutic effect of Mongolian medical warm acupuncture in treating the patients with insomnia accompanied with depression and discuss the mechanism of action of Mongolian medical warm acupuncture in treating insomnia. Method 50 patients with insomnia accompanied with depression were clinically selected and randomly divided into the Mongolian medical warm acupuncture group and the drug group (trazodone) of 25 each. The patients in the Mongolian medical warm acupuncture group were subjected to acupoint stimulation (Xin acupoint, Dinghui acupoint, and Heyi) for 30 min once a day. 100mg of trazodone were administered to the patients in the drug group. The patients in both groups were treated for 4 weeks. The patients in both groups were compared in terms of Pittsburgh sleep quality index, sleep quality, daytime functions, self-rating depression scale etc. Result There was a significant difference in total score of Pittsburgh sleep quality index (PSQI) between the patients in the Mongolian medical warm acupuncture group before treatment (16.83±3.68) and those after treatment (8.18±3.78)(P<0.01). The scores of sleep quality and daytime functions of the patients in the Mongolian medical warm acupuncture group (6.76±2.76) were superior to those in the drug group (5.89±2.87)(P<0.05). The self-rating depression scale (SDS) scores of the patients in the Mongolian medical warm acupuncture group after treatment (0.54±0.89) decreased significantly when compared with those before treatment (P<0.01). There was no significant difference in clinical therapeutic effect between both groups (P=0.0812>0.05). The obvious curative rate in the Mongolian medical warm acupuncture group (75.58%) was significantly superior to that in the drug group (49.77%) (P=0.0382<0.05). The Asberg side effect rating scale (SERS) score in the drug group after treatment (6.11±2.06) was significantly higher than that in the Mongolian medical warm acupuncture group (4.15±1.98) (P<0.05). Conclusion Mongolian medical warm acupuncture has therapeutical effect on insomnia accompanied with depression and Mongolian medical warm acupuncture has better therapeutical effect and fewer side effects than trazodone. Mongolian medical warm acupuncture has certain sedative-hypnotic and anti-depressive effects applies to insomnia accompanied with suppression.

show abstract

Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded,prospective study

Cited by 31 publications

References 93 publications

Treating to target in major depressive disorder: response to remission to functional recovery

Treating to target in major depressive disorder: response to remission to functional recovery

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update

Research on Treating Insomnia Accompanied With Depression by Mongolian Medical Warm Acupuncture

Contact Info

Product

Resources

About